190 related articles for article (PubMed ID: 34273443)
1. The gene expression of GPER1 is low in fresh samples of papillary thyroid carcinoma (PTC), and in silico analysis.
Bertoni APS; Manfroi PA; Tomedi J; Assis-Brasil BM; de Souza Meyer EL; Furlanetto TW
Mol Cell Endocrinol; 2021 Sep; 535():111397. PubMed ID: 34273443
[TBL] [Abstract][Full Text] [Related]
2. Decreased Expression of Estrogen Receptors Is Associated with Tumorigenesis in Papillary Thyroid Carcinoma.
Chou CK; Chi SY; Hung YY; Yang YC; Fu HC; Wang JH; Chen CC; Kang HY
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35162942
[TBL] [Abstract][Full Text] [Related]
3. High expression of GPER1, EGFR and CXCR1 is associated with lymph node metastasis in papillary thyroid carcinoma.
Tang C; Yang L; Wang N; Li L; Xu M; Chen GG; Liu ZM
Int J Clin Exp Pathol; 2014; 7(6):3213-23. PubMed ID: 25031742
[TBL] [Abstract][Full Text] [Related]
4. GPER1 in the thyroid: A systematic review.
Manfroi PA; Bertoni APS; Furlanetto TW
Life Sci; 2020 Jan; 241():117112. PubMed ID: 31790688
[TBL] [Abstract][Full Text] [Related]
5. Hypermethylation of the RSK4 promoter associated with BRAF V600E promotes papillary thyroid carcinoma.
Yin Y; Che K; Hu J; Hua H; Dong A; Wang J; Yu J; Zhang Q; Zhao S; Zhao Y; Wang P; Wang F; Wang Y; Chi J; Sun W
Int J Oncol; 2020 May; 56(5):1284-1293. PubMed ID: 32319586
[TBL] [Abstract][Full Text] [Related]
6. New global analysis of the microRNA transcriptome of primary tumors and lymph node metastases of papillary thyroid cancer.
Saiselet M; Gacquer D; Spinette A; Craciun L; Decaussin-Petrucci M; Andry G; Detours V; Maenhaut C
BMC Genomics; 2015 Oct; 16():828. PubMed ID: 26487287
[TBL] [Abstract][Full Text] [Related]
7. LIMD2 Is Overexpressed in BRAF V600E-Positive Papillary Thyroid Carcinomas and Matched Lymph Node Metastases.
Pinheiro Dos Santos MJC; Bastos AU; da Costa VR; Delcelo R; Lindsey SC; Colozza-Gama GA; Peng H; Rauscher FJ; Oler G; Cerutti JM
Endocr Pathol; 2018 Sep; 29(3):222-230. PubMed ID: 29560564
[TBL] [Abstract][Full Text] [Related]
8. Upregulation of endocrine gland-derived vascular endothelial growth factor in papillary thyroid cancers displaying infiltrative patterns, lymph node metastases, and BRAF mutation.
Pasquali D; Santoro A; Bufo P; Conzo G; Deery WJ; Renzullo A; Accardo G; Sacco V; Bellastella A; Pannone G
Thyroid; 2011 Apr; 21(4):391-9. PubMed ID: 21385081
[TBL] [Abstract][Full Text] [Related]
9. Activity of ecto-5'-nucleotidase (NT5E/CD73) is increased in papillary thyroid carcinoma and its expression is associated with metastatic lymph nodes.
Bertoni APS; Bracco PA; de Campos RP; Lutz BS; Assis-Brasil BM; Meyer ELS; Saffi J; Braganhol E; Furlanetto TW; Wink MR
Mol Cell Endocrinol; 2019 Jan; 479():54-60. PubMed ID: 30184475
[TBL] [Abstract][Full Text] [Related]
10. Correlation among the BRAF gene mutation status, clinicopathological features of primary tumour, and lymph node metastasizing of papillary thyroid carcinoma.
Lukas J; Drabek J; Dudesek B; Vazan P; Stranska J; Jancik S; Mackova M; Syrucek M; Lukas D; Duskova J; Dundr P; Hintnausova B; Jiskra J
Exp Clin Endocrinol Diabetes; 2014 May; 122(5):268-72. PubMed ID: 24839220
[TBL] [Abstract][Full Text] [Related]
11. Significance of the BRAF mRNA Expression Level in Papillary Thyroid Carcinoma: An Analysis of The Cancer Genome Atlas Data.
Chai YJ; Yi JW; Jee HG; Kim YA; Kim JH; Xing M; Lee KE
PLoS One; 2016; 11(7):e0159235. PubMed ID: 27410688
[TBL] [Abstract][Full Text] [Related]
12. LncRNA ENST00000539653 acts as an oncogenic factor via MAPK signalling in papillary thyroid cancer.
Song B; Li R; Zuo Z; Tan J; Liu L; Ding D; Lu Y; Hou D
BMC Cancer; 2019 Apr; 19(1):297. PubMed ID: 30940124
[TBL] [Abstract][Full Text] [Related]
13. BRAF(V600E) mutation in Turkish patients with papillary thyroid cancer: strong correlation with indicators of tumor aggressiveness.
Kurtulmus N; Duren M; Ince U; Cengiz Yakicier M; Peker O; Aydın O; Altiok E; Giray S; Azizlerli H
Endocrine; 2012 Oct; 42(2):404-10. PubMed ID: 22426956
[TBL] [Abstract][Full Text] [Related]
14. Association between diffuse lymphocytic infiltration and papillary thyroid cancer aggressiveness according to the presence of thyroid peroxidase antibody and BRAF
Lee YK; Park KH; Park SH; Kim KJ; Shin DY; Nam KH; Chung WY; Lee EJ
Head Neck; 2018 Oct; 40(10):2271-2279. PubMed ID: 29935011
[TBL] [Abstract][Full Text] [Related]
15. BRAF V600E mutation and its association with clinicopathological features of papillary thyroid cancer: a meta-analysis.
Li C; Lee KC; Schneider EB; Zeiger MA
J Clin Endocrinol Metab; 2012 Dec; 97(12):4559-70. PubMed ID: 23055546
[TBL] [Abstract][Full Text] [Related]
16. BRAF
Shi C; Cao J; Shi T; Liang M; Ding C; Lv Y; Zhang W; Li C; Gao W; Wu G; Man J
World J Surg Oncol; 2020 Jun; 18(1):145. PubMed ID: 32593310
[TBL] [Abstract][Full Text] [Related]
17. Elevated BANCR expression levels have different effects on papillary thyroid carcinoma progression depending on the presence of the BRAFV600E mutation.
Stojanović S; Šelemetjev S; Đorić I; Rončević J; Janković Miljuš J; Živaljević V; Išić Denčić T
Eur J Surg Oncol; 2020 Oct; 46(10 Pt A):1835-1842. PubMed ID: 32651027
[TBL] [Abstract][Full Text] [Related]
18. A meta-analysis evaluating the relationship between B-type Raf kinase mutation and cervical lymphatic metastasis in papillary thyroid cancer.
Ma H; Wang R; Fang J; Zhong Q; Chen X; Hou L; Feng L; Chen X; Huang Z; Zhao H
Medicine (Baltimore); 2020 Jan; 99(5):e18917. PubMed ID: 32000400
[TBL] [Abstract][Full Text] [Related]
19. Imbalance in DNA repair machinery is associated with BRAF
Lutz BS; Leguisamo NM; Cabral NK; Gloria HC; Reiter KC; Agnes G; Zanella V; Meyer ELS; Saffi J
Mol Cell Endocrinol; 2018 Sep; 472():140-148. PubMed ID: 29229408
[TBL] [Abstract][Full Text] [Related]
20. Gene expression profiling of papillary thyroid carcinoma identifies transcripts correlated with BRAF mutational status and lymph node metastasis.
Oler G; Camacho CP; Hojaij FC; Michaluart P; Riggins GJ; Cerutti JM
Clin Cancer Res; 2008 Aug; 14(15):4735-42. PubMed ID: 18676742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]